John Park never inspected a rat-infested warehouse himself. He ran Acme Markets from a desk in Philadelphia, delegated food safety to subordinates, and still ended up a convicted federal criminal.
The Supreme Court upheld his 1975 conviction anyway, and the doctrine that carries his name now reaches into boardrooms at pharmaceutical and medical device companies across the country.
Under 21 U.S.C. § 333, a pharmaceutical executive who never read a batch record, never approved a mislabeled insert, and never attended a meeting where a violation was discussed can still be convicted of a federal misdemeanor.
Prosecutors do not have to prove intent. They do not have to prove knowledge. They only have to prove the executive held a position of authority over the part of the company where the violation happened.
What Is the Park Doctrine Under 21 U.S.C. § 333?
The Federal Food, Drug, and Cosmetic Act splits criminal liability into two tiers.
- Section 333(a)(1) makes a first violation a misdemeanor, punishable by up to a year in prison and a modest statutory fine, without any requirement to show fraudulent intent.
- Section 333(a)(2) reserves felony punishment, up to three years, for conduct done with the intent to defraud or mislead consumers or the FDA itself.
Essentially, the misdemeanor tier exists to catch people the felony tier cannot reach. The Ninth Circuit called this a form of strict criminal liability in United States v. Watkins, and the Justice Department's own Consumer Protection Branch confirms it in plain language: an individual who stands in responsible relation to a violation can be liable even without personal involvement.
That individual liability theory is the Park Doctrine, sometimes called the responsible corporate officer doctrine.
How Does § 333 Treat Executives Differently Than Companies?
A company faces corporate exposure no matter who inside it broke the rules. An executive faces something narrower and, in some ways, harsher: personal criminal exposure tied directly to a job title.
Courts require prosecutors to establish two things before a Park Doctrine conviction sticks:
- A prohibited act took place somewhere inside the company.
- The executive's position gave them the authority and responsibility to prevent or correct that violation, and they failed to act.
That second element does not ask what the executive knew. It asks what the executive could have done.
A chief operating officer who delegates quality control to a plant manager can still answer for what that plant manager missed. But delegation does not erase authority, and authority is what the statute actually punishes.
Why Does the FDA Use Misdemeanor Charges Instead of Felonies?
Leverage. A felony charge under § 333(a)(2) requires the government to prove intent to defraud, which is expensive and uncertain at trial. A misdemeanor charge requires only proof of position and violation, far easier to establish and far easier to negotiate around.
FDA's Office of Criminal Investigations refers cases to the Justice Department once the normal regulatory process has failed and the risk to public health looks significant. In March 2024, a Pennsylvania generic drug manufacturer pleaded guilty to two misdemeanor counts of introducing adulterated drugs into interstate commerce, agreeing to a $1.5 million penalty while its corporate affiliate entered a deferred prosecution agreement. No felony intent was alleged. The misdemeanor charge alone carried enough weight to force a resolution.
What Happens After a Misdemeanor FDCA Conviction?
A misdemeanor sounds minor until the collateral consequences arrive.
- Federal prison exposure of up to one year, or up to three years if the government proves intent to defraud or the executive has a prior § 333 conviction.
- Exclusion from Medicare, Medicaid, and every other federal health care program under 42 U.S.C. § 1320a-7(b), sometimes for a decade or longer.
- FDA debarment, which can bar an executive from working in any capacity connected to drug approval or manufacturing.
- Permanent damage to the executive's standing with the board, investors, and any licensing body that reviews criminal history.
For a physician or pharmacist who also holds an executive title, a misdemeanor conviction can trigger a separate inquiry from that professional's licensing board, layered on top of the criminal case itself.
Can an Executive Be Charged Without Personal Knowledge of the Violation?
Yes, and that is precisely what makes § 333 dangerous for people who believe compliance is someone else's job.
In United States v. DeCoster, the Eighth Circuit upheld misdemeanor convictions against two egg company executives even though the government acknowledged they did not know their product was contaminated.
Their authority over the operation was enough. The same reasoning applies inside a pharmaceutical company: an executive who never saw a contaminated batch record can still answer for it in federal court.
Where this gets worse is when an executive learns of a problem after the fact and reacts badly. Deleting records, allowing an automated retention policy to purge relevant files, or failing to issue a litigation hold once an FDA inquiry begins can escalate a misdemeanor exposure into obstruction of justice charges under 18 U.S.C. § 1519, a felony carrying up to twenty years.
Related Federal Laws
Federal prosecutors rarely investigate or charge a Park Doctrine misdemeanor under 21 U.S.C. § 333 in complete isolation.
During a regulatory audit or criminal investigation, executive post-conduct—such as deleting emails, altering inspection logs, or shading answers during an interview—can quickly transform a strict liability misdemeanor carrying a 1-year ceiling into severe felony charges like obstruction of justice (18 U.S.C. § 1519) or making false statements (18 U.S.C. § 1001), which carry up to 5 to 20 years in federal prison.
Furthermore, when product safety issues overlap with marketing, off-label promotion, or Medicare billing, the government frequently pairs FDCA allegations with Health Care Fraud (18 U.S.C. § 1347) and Anti-Kickback violations to compound an executive's sentencing exposure and force high-stakes plea negotiations. The related laws include:
-
21 U.S.C. § 331 – Prohibited Acts Under the FDCA: The foundational statute that explicitly forbids introducing adulterated or misbranded foods, drugs, or medical devices into interstate commerce, as well as altering or destroying product labels. Section 331 acts as the primary predicate offense that triggers criminal penalties under 21 U.S.C. § 333.
-
18 U.S.C. § 1001 – False Statements to Federal Investigators: Prohibits knowingly making materially false, fictitious, or fraudulent statements or submitting falsified documents to any branch of the federal government, including FDA inspectors or federal agents.
-
18 U.S.C. § 1519 – Destruction, Alteration, or Falsification of Records in Federal Investigations: A felony statute under Sarbanes-Oxley that criminalizes knowingly altering, destroying, mutilating, concealing, or falsifying records with the intent to impede or obstruct an ongoing or prospective federal investigation.
-
42 U.S.C. § 1320a-7b(b) – Anti-Kickback Statute (AKS): Makes it a federal crime to knowingly and willfully offer, pay, solicit, or receive any remuneration to induce or reward referrals for items or services payable by federal healthcare programs like Medicare or Medicaid.
-
18 U.S.C. § 1347 – Health Care Fraud: Prohibits knowingly and willfully executing a scheme to defraud any healthcare benefit program or obtaining money or property owned by a healthcare benefit program through false pretenses, representations, or promises.
Frequently Asked Questions (FAQs)
What is the Park Doctrine under 21 U.S.C. § 333?
The Park Doctrine, also known as the Responsible Corporate Officer (RCO) doctrine, allows federal prosecutors to hold corporate executives criminally liable for violations of the Federal Food, Drug, and Cosmetic Act (FDCA) under 21 U.S.C. § 333. An executive can be convicted of a misdemeanor even without personal knowledge, participation, or intent to commit a violation, simply by holding a position of authority over the division where the violation occurred.
Can an executive go to prison if they didn't know a violation happened?
Yes. Under 21 U.S.C. § 333(a)(1), misdemeanor convictions do not require proof of intent or personal knowledge. If a corporate officer possessed the authority and responsibility to prevent or correct an FDCA violation and failed to do so, they can face up to one year in federal prison per count.
What is the difference between a misdemeanor and a felony under 21 U.S.C. § 333?
Section 333(a)(1) makes a first violation a misdemeanor without requiring proof of fraudulent intent. Section 333(a)(2) elevates the offense to a felony, punishable by up to three years in prison, if the government proves the executive acted with the specific intent to defraud or mislead consumers or regulatory agencies like the FDA.
What collateral consequences follow an FDCA misdemeanor conviction?
Beyond fines and jail time, a misdemeanor conviction under § 333 can trigger mandatory or permissive exclusion from federal healthcare programs under 42 U.S.C. § 1320a-7, FDA debarment, loss of state professional licenses (for physicians or pharmacists), and permanent reputational damage with investors and boards.
How does the FDA determine which executives to charge under the Park Doctrine?
The FDA and the Department of Justice evaluate several factors, including the executive's position within the organizational hierarchy, their authority to prevent or correct the violation, the severity of the public health risk, and whether the company failed to respond adequately to prior warnings, such as FDA Form 483s or warning letters.
Can delegating compliance duties to a subordinate protect an executive from liability?
No. Delegation of authority does not absolve an executive of criminal responsibility under the Park Doctrine. Federal courts hold that while operational duties can be delegated, ultimate corporate authority remains with the executive, making them legally responsible for failures within their scope of authority.
What is the "impossibility defense" in a Park Doctrine prosecution?
The impossibility defense is a narrow legal strategy where an executive argues that they were genuinely powerless to prevent or correct the violation due to circumstances entirely beyond their control. Courts interpret this defense extremely strictly, requiring clear evidence that the officer exercised extraordinary diligence yet could not stop the prohibited act.
How can defense attorneys protect an executive before formal charges are filed?
Attorneys can conduct prefiling interventions to present evidence of a functioning compliance program directly to federal prosecutors. Defense counsel can document the executive's actual sphere of authority, highlight prompt remedial measures or voluntary recalls, and attempt to resolve allegations through corporate agreements rather than individual criminal charges.
What Defense Strategies Apply to a Park Doctrine Case?
The best defense work happens before an indictment exists. Park Doctrine prosecutions sit inside a broader category of federal white collar cases built around personal accountability rather than corporate liability alone.
Prefiling intervention lets defense counsel present evidence of a genuine, working compliance program directly to the prosecutor's office, sometimes persuading the government not to file at all, or to resolve the matter through a corporate agreement instead of an individual charge.
A strong defense typically attacks the "responsible relation" element head-on, documenting exactly what authority an executive had, what they delegated, and what remedial steps followed once a problem surfaced.
Executives facing overlapping exposure, such as allegations of federal health care fraud under 18 U.S.C. § 1347, Anti-Kickback Statute violations, or federal mail fraud under 18 U.S.C. § 1341, need a strategy that considers the whole picture, not the misdemeanor count in isolation.
The Regional VP Who Trusted the Wrong Vendor
A regional vice president at a mid-sized medical device company approves a new overseas supplier for a sterile component after receiving a quality assurance sign-off from her director of manufacturing.
She never reviews the underlying inspection reports herself. Eighteen months later, FDA inspectors find that the supplier's facility failed sterility testing on three separate occasions, and none of those failures were escalated past the manufacturing director.
The government charges the vice president under 21 U.S.C. § 333(a)(1), arguing that her title and budget authority over the manufacturing division made her a responsible corporate officer regardless of what she personally reviewed. She never signed a single inspection report.
Defense counsel focuses on two things: the company's documented approval chain, which shows the director had independent sign-off authority and a duty to escalate failures, and the vice president's immediate response once the sterility issue surfaced, including a voluntary recall and a rebuilt inspection protocol. That response becomes the centerpiece of a negotiated resolution that keeps the case out of a courtroom and off the front page.
Park Doctrine exposure rarely announces itself. It shows up in an FDA warning letter, an informal inquiry, or a subpoena addressed to someone three levels below the executive who eventually gets charged.
And by the time the government names an individual, the company's own records have often already shaped the case against that person.
For more information on how to protect yourself from similar accusations, contact the attorneys at Eisner Gorin LLP today for a confidential consultation.
